Department of Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Transpl Int. 2018 Dec;31(12):1369-1379. doi: 10.1111/tri.13318. Epub 2018 Aug 1.
Early histological progression that associates with delayed graft function (DGF) and its relationship to graft outcomes is less well-understood. We systematically evaluated early acute and chronic histological changes associated with DGF through serial biopsies (protocol: 3 and 12 months; for-cause) and related them to graft outcomes. 56/294 (19.04%) of our patients had DGF. DGF was associated with a progressive increase in both Banff 't' and 'i' scores from 2 weeks to 3 and 12 months with a resultant increase in T cell mediated rejection (TCMR) that was significantly greater than those with primary graft function (PGF). This increase in TCMR was predominantly sub-clinical TCMR diagnosed on protocol biopsy. Furthermore, TCMR in patients with DGF was recurrent/persistent at 12 months. Importantly, the combination of DGF and TCMR was associated with significantly worse interstitial fibrosis and tubular atrophy (IFTA) and interstitial fibrosis with inflammation (IF + 'i') as early as 3 months and worse renal function. Finally, DGF with TCMR was associated with significantly worse graft loss. In this regard, DGF without TCMR had comparable chronic histology and outcomes to PGF. Thus, DGF with TCMR (predominantly sub-clinical), represents a high-risk patient group who may benefit from early novel immunosuppression augmentation strategies to improve graft outcomes.
早期组织学进展与延迟移植物功能(DGF)及其与移植物结局的关系尚不清楚。我们通过系列活检(方案:3 个月和 12 个月;因病因)系统地评估了与 DGF 相关的早期急性和慢性组织学变化,并将其与移植物结局相关联。我们的 294 名患者中有 56 名(19.04%)发生 DGF。DGF 与 Banff 't' 和 'i' 评分从 2 周到 3 个月和 12 个月的逐渐增加相关,导致 T 细胞介导的排斥反应(TCMR)增加,显著高于原发性移植物功能(PGF)。这种 TCMR 的增加主要是在方案活检中诊断为亚临床 TCMR。此外,DGF 患者的 TCMR 在 12 个月时复发/持续存在。重要的是,DGF 和 TCMR 的组合与 3 个月时明显更差的间质纤维化和肾小管萎缩(IFTA)和间质纤维化伴炎症(IF + 'i')以及更差的肾功能相关。最后,DGF 伴 TCMR 与移植物丢失显著相关。在这方面,无 TCMR 的 DGF 与 PGF 的慢性组织学和结局相当。因此,DGF 伴 TCMR(主要为亚临床)代表了一个高危患者群体,可能受益于早期新型免疫抑制增强策略以改善移植物结局。